AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease
23 avr. 2024 06h00 HE
|
Averoa
Grenoble, France, 23rd April 2024 - Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, announces the submission of a marketing authorisation...
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
15 mars 2024 07h05 HE
|
Arch Biopartners
TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of...
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
07 mars 2024 07h26 HE
|
Arch Biopartners
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in...
Dr. Lisandro Montalvo-Burke Joins Healthmap Solutions as Medical Director for Puerto Rico
13 févr. 2024 08h00 HE
|
Healthmap Solutions
Healthmap Solutions, Inc. has named Lisandro Montalvo-Burke, MD as its new Medical Director in Puerto Rico.
France Kidney Function Tests Market Forecasts & Opportunities 2018-2028: Dipsticks and Hospitals & Clinics Secure Leading Positions
30 janv. 2024 07h51 HE
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "France Kidney Function Tests Market, By Region, By Competition Forecast & Opportunities, 2018-2028F" report has been added to ...
Kidney Renal Function Test Market Size Worth USD 1,599.0 Million in 2032 | Emergen Research
29 janv. 2024 09h55 HE
|
Emergen Research
Vancouver, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The global kidney/renal function test market size was USD 845.9 Million in 2022 and is expected to register a revenue CAGR of 6.5% during the forecast...
Global Chronic Kidney Disease Market Poised for Growth, Projected to Reach $83.6 Billion by 2030
23 janv. 2024 03h08 HE
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. ...
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
03 janv. 2024 16h13 HE
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
21 déc. 2023 07h30 HE
|
Arch Biopartners
TORONTO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Kocaeli...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
07 déc. 2023 07h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...